Pax5 as a potential candidate marker for canine B-cell lymphoma

Sirivisoot, Sirintra; Techangamsuwan, Somporn; Tangkawattana, Sirikachorn; Rungsipipat, Anudep

doi:10.17221/100/2016-vetmed

Cited by 7 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunostaining with CD3, CD20 and Pax5 and/or a clonality test were performed for lymphoma subtype classification following REAL/WHO (Revised European American Lymphoma/World Health Organization) 1 . The immunohistochemistry for CD20, CD3 and Pax5 was adapted from a previous study 28 . Briefly, tissue section was quenched endogenous peroxidase by 0.3% (v/v) H 2 O 2 for 30 min and 5% bovine serum albumin was used for non-specific blocking for 20 min.…”

Section: Methodsmentioning

confidence: 99%

Evaluation of 41 single nucleotide polymorphisms in canine diffuse large B-cell lymphomas using MassARRAY

Sirivisoot

Kasantikul

Techangamsuwan

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma in dogs with a multicentric form. This study aimed to assemble 41 variants of the previously reported genes and to investigate these variants in canine DLBCL using the Agena MassARRAY platform. These variants were chosen based on the high prevalence observed in canine B- and T-cell lymphomas, their significance for target therapy, and compatibility for multiplex PCR amplification. Lymph node biopsy was performed from 60 dogs with B-cell lymphoma comprising 47 purebred and 13 crossbred dogs. All dogs presented single nucleotide polymorphisms (SNPs) at HYAL4 and SATB1 genes. The lesser mutual SNPs were observed at SEL1L, excluding a cocker spaniel, and c-Kit, with the exception of a pug and a French bulldog. Even though no statistical association was noted between each SNP and dog breed, purebreds were 3.88 times more likely to have a SNP at FLT3 rs852342480 (95%CI 0.50–45.03, p = 0.26), 3.64 times at TRAF3 F306X (95%CI 0.58–42.50, p = 0.43) and 2.66 times at TRAF3 E303EX (95%CI 0.56–13.12, p = 0.31). Also, DLBCL dogs (CHOP-based treatment) with c-Kit T425= had a poorer prognosis with shorter median overall survival times (OST) than dogs with the wild type. Dogs treated with COP chemotherapy and contained 3–5 variants at SEL1L were associated with decreased median OST. Therefore, this SNP’s lymphoma panel provides valuable information that we can use to outline a prognosis and develop a treatment plan for the targeted therapy of each dog.

show abstract

Section: Methodsmentioning

confidence: 99%

Evaluation of 41 single nucleotide polymorphisms in canine diffuse large B-cell lymphomas using MassARRAY

Sirivisoot

Kasantikul

Techangamsuwan

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The histopathological classification was categorized according to the Revised European American Lymphoma (REAL)/WHO [ 2 ]. The immunohistochemistry against CD3 and Pax5 for T and B lymphocyte markers was performed based on the previous report [ 18 ].…”

Section: Methodsmentioning

confidence: 99%

Investigation of proteomic profiles in canine lymphoma using tandem mass tag-based quantitative proteomics approach

et al. 2022

View full text Add to dashboard Cite

Background and Aim: Specific tumor biomarkers are useful for the early diagnosis of cancer or can predict the recurrence of neoplastic disease in humans and animals. Lymphoma in dogs could be classified into B-, T-, and NK-cell origins. T-cell lymphoma has the worst prognosis with a shorter survival time and disease-free interval. This study aimed to identify the differential serum protein expressions of canine B- and T-cell lymphomas compared with healthy dogs using a tandem mass tag (TMT)-based quantitative proteomics. Materials and Methods: Serum samples were collected from 20 untreated canine lymphomas (14 B-cells and 6 T-cells) and four healthy control dogs. Sera peptides from each sample were processed for TMT 10-plex tagging and analyzed using liquid chromatography-mass spectrometry (MS). Differential proteome profiling was then compared between lymphoma and control. Results: We discovered 20 elevated and 14 decreased serum proteins in the lymphoma group relative to the healthy group. Six candidate increased proteins in canine lymphomas were beta-actin cytoplasmic 1 (ACTB, p=0.04), haptoglobin (p=0.002), beta-2 microglobulin (β2M, p=0.007), beta-2 glycoprotein 1 (APOH, p=0.03), metalloproteinase inhibitor 1 (TIMP-1, p=0.03), and CD44 antigen (p=0.02). When compared between B- and T-cell lymphomas, B-cell phenotypes had upregulated immunoglobulin (Ig) heavy chain V region GOM (p=0.02), clusterin (p=0.01), apolipoprotein C1 (APOC1, p=0.05), and plasminogen (p=0.02). Conclusion: These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs. However, evaluation with an increased sample size is needed to confirm their diagnostic and prognostic ability.

show abstract

“…Pax5 showed a nuclear staining in B cells while CD3 showed immunoreactivity in the cytoplasm of T cells. B-cell or T-cell lymphomas were identified if at least 60% of the cells revealed expression of Pax5 or CD3, respectively (Sirivisoot et al, 2017).…”

Section: Immunocytochemistry (Icc)mentioning

confidence: 99%

“…A normal canine lymph node obtained from necropsy was used as a staining control. Interpretations of positive B-cell or T-cell lym-Acta Veterinaria Hungarica 66, 2018 phomas were achieved when at least 60% of the neoplastic cells stained positive with Pax5 and CD3, respectively (Sirivisoot et al, 2017).…”

Section: Immunohistochemistry (Ihc)mentioning

confidence: 99%

Monitoring minimal residual disease in canine lymphomas treated with modified L-COP or L-CHOP protocols

Sirivisoot

Teewasutrakul

Techangamsuwan

et al. 2018

Acta Veterinaria Hungarica

View full text Add to dashboard Cite

Heteroduplex polymerase chain reaction for antigen receptor rearrangements (hPARR) was developed to monitor minimal residual disease (MRD) in canine B- and T-cell lymphomas treated with the modified L-COP or L-CHOP protocol. Thirty-five dogs were recruited in this study and their neoplastic lineages were determined by immunophenotyping with Pax5 and CD3. Peripheral blood leukocytes were collected prior to and during chemotherapy in weeks 4, 9 and 13 to detect MRD by hPARR. Twenty-eight dogs (80%) had B-cell lymphoma while seven dogs (20%) had T-cell lymphoma. A monoclonal band was detected in 11 cases that showed complete or partial remission before tumour relapse and no response to the current treatment without statistical difference in clinical outcomes; however, the treatment response had an association with the MRD result (P < 0.05). Modified L-CHOP prolonged median progression-free survival as compared to modified L-COP (215 days vs. 93 days; P < 0.05). Substage b had shorter progression-free survival than substage a (90 days vs. 215 days; P < 0.05). Clinical stage III affected median overall survival time when compared to clinical stages IV and V (432, 173 and 118 days, respectively; P < 0.05). hPARR could be used for screening refractory lymphoma together with lymph node measurement in routine clinical cases.

show abstract

Pax5 as a potential candidate marker for canine B-cell lymphoma

Cited by 7 publications

References 27 publications

Evaluation of 41 single nucleotide polymorphisms in canine diffuse large B-cell lymphomas using MassARRAY

Evaluation of 41 single nucleotide polymorphisms in canine diffuse large B-cell lymphomas using MassARRAY

Investigation of proteomic profiles in canine lymphoma using tandem mass tag-based quantitative proteomics approach

Monitoring minimal residual disease in canine lymphomas treated with modified L-COP or L-CHOP protocols

Contact Info

Product

Resources

About